Scarica l'app Stockscreener
3.98
0.75%
-0.03
Dopo l'orario di chiusura:
4.08
0.10
+2.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8%What's Next? - MarketBeat
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Rises on Patent Dispute Jury Trial Deci - GuruFocus
Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Aug Drivers: Can Arbutus Biopharma Corporation ride the EV waveQuarterly Investment Review & Consistent Return Strategy Ideas - baoquankhu1.vn
Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Aug Closing: Should I buy Arbutus Biopharma Corporation stock nowJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O - GuruFocus
Arbutus Biopharma (ABUS) Faces Patent Revocation in Europe - GuruFocus
ABUS Stock Tumbles on European Patent Revocation - StocksToTrade
Arbutus Biopharma (ABUS) Shares Drop Amid Patent Revocation - GuruFocus
Market Dynamics Cause Shifts for Arbutus Biopharma - StocksToTrade
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash - Intellectia AI
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Arbutus (ABUS) upgraded to buy: Here's what you should know - MSN
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Arbutus Biopharma Shares Fall 19% On European Patent Revocation - Nasdaq
Arbutus Biopharma (ABUS) Patent Revocation Leads to 14% Pre-Market Drop - Intellectia AI
European Patent Office revokes Arbutus Biopharma patent following appeal - Investing.com
Arbutus Biopharma CorpEPO revokes Arbutus Biopharma's European patent EP 2279254SEC filing - marketscreener.com
Weekly Trades: Will Arbutus Biopharma Corporation stock gain from lower inflationTrade Signal Summary & Stock Market Timing Techniques - Bộ Nội Vụ
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How sustainable is Arbutus Biopharma Corporation stock dividend payoutBear Alert & Safe Entry Momentum Stock Tips - Улправда
Why Arbutus Biopharma Corporation stock is popular among millennialsQuarterly Portfolio Summary & Long-Term Growth Plans - Улправда
New Highs: Why Arbutus Biopharma Corporation stock is popular among millennialsEarnings Miss & Growth-Oriented Investment Plans - Улправда
What is the fair value of Arbutus Biopharma Corporation stock nowWeekly Trading Summary & Weekly Momentum Picks - Улправда
Will Arbutus Biopharma Corporation stock deliver shareholder valueWeekly Market Report & Fast Entry Momentum Alerts - Улправда
How Arbutus Biopharma Corporation stock reacts to Fed rate cutsQuarterly Portfolio Summary & Weekly High Momentum Picks - Улправда
Is Arbutus Biopharma Corporation stock supported by strong fundamentals2025 Pullback Review & Consistent Income Trade Recommendations - Улправда
Why Arbutus Biopharma Corporation stock is seen as undervaluedProduct Launch & Low Drawdown Trading Strategies - Улправда
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Hepatitis B Market to Witness Promising Upswing by 2034, - openPR.com
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Arbutus Biopharma (NASDAQ:ABUS) Shares Up 6%Still a Buy? - MarketBeat
Pharma Patent Trials Loom in 2026 for Wegovy, Covid-Vaccine Tech - Mintz
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Why Arbutus Biopharma Corporation stock is rated strong buyEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
ABUS (Arbutus Biopharma) OCF Margin % : -1,099.62% (As of Sep. 2025) - GuruFocus
Is Arbutus Biopharma Corporation stock ready for breakoutCEO Change & Reliable Entry Point Alerts - ulpravda.ru
Does Arbutus Biopharma Corporation stock trade at a discount to peersPortfolio Update Report & Weekly Watchlist of Top Performers - Улправда
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4%What's Next? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.6%Should You Buy? - MarketBeat
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView — Track All Markets
[8-K] Arbutus Biopharma Corp Reports Material Event | ABUS SEC FilingForm 8-K - Stock Titan
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
New Haven biotech names new CFO - Hartford Business Journal
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):